The World Health Organization has clearly stated that couples of normal reproductive age who have had regular sexual intercourse without contraception for more than one year and still have not conceived can be diagnosed as infertile. The incidence of infertility in married couples is about 15%, of which 50% is caused by male factors, called male infertility. In recent years, as people’s awareness of human reproductive problems and the rapid development of male science, the detection rate of male infertility has gradually increased, has attracted the great attention of male scientists. Since the birth of the world’s first “test tube baby” in 1978 by in vitro fertilization (IVF) by LDuise Brown in the UK, assisted reproductive technology (ART) has gradually become an important treatment for infertile couples. ICSI (intracytoplasmic sperm injection), germ cell and embryo freezing techniques, etc. To date, 5 million IVF babies have been born worldwide. For male infertility, in vitro fertilization and embryo transfer (IVFDET) and intracytoplasmic sperm injection (ICSI) are the most effective treatments for many causes of male infertility, such as partial azoospermia, severe oligozoospermia and moderate oligozoospermia, etc. The ICSI technique involves certain genetic risks, and to reduce these risks, rigorous genetic testing should be performed, mainly karyotype analysis, cystic fibrosis gene mutation analysis and molecular detection of Y chromosome microdeletion, etc. Combined with pre-implantation genetic testing and prenatal diagnosis, its for spermless men who need donor sperm to bring hope of having their own babies. In vitro fertilization (IVF) and intracytoplasmic single sperm injection (ICSI) at the Center for Reproductive Medicine, Nantong University Hospital Song Jian is a more complex technique than IUI, removing more of the hardships and risks that sperm encounter in the female reproductive tract. IVF involves a process of controlled ovulation promotion, and transvaginal acquisition of follicles by ultrasound guidance prior to normal ovulation. This technique addresses fertility barriers in moderate and severe infertility with low sperm density. A recent revolutionary advancement in IVF is the microinjection of sperm (ICSI) technique, which has facilitated the development of sperm retrieval for patients with azoospermia. Indications for in vitro fertilization-embryo transfer (IVF-ET) 1 Mild to moderate oligozoospermia, combined with severe teratozoospermia. 2 Mild to moderate oligozoospermia without severe teratozoospermia, failed after 3-4 IUI cycles. 3 Unexplained infertility, failed after 3-4 IUI cycles. 4 Immunological infertility, failed after 3-4 IUI cycles with intracytoplasmic monosperm Indications for microinjection (ICSI) ①severe oligospermia, weakness, and teratospermia; ②irreversible obstructive azoospermia; ③spermatogenic dysfunction (excluding those caused by genetic defect diseases); ④immune infertility; ⑤failure of in vitro fertilization; ⑥abnormal sperm acrosome; ⑦need for preimplantation embryo genetic examination Pre-implantation genetic diagnosis Pre-implantation genetic diagnosis is a highly specific test that can precisely determine the genetic norm of the embryo. Some patients, through IVF and ICSI techniques, may pass on heritable and life-threatening diseases to their offspring. For pre-implantation genetic diagnosis, individual cells are obtained from early embryos in a covered culture dish. The genetic material obtained from the cells is then tested to determine if the embryo under test carries abnormal chromosomes or genes. With the help of pre-implantation genetic diagnosis, early embryos resulting from IVF and ICSI can be individually examined for the presence of suspected genetic traits. Due to their real-time nature, it is possible to determine within 24h whether to proceed with embryo transfer to ensure that lethal diseases are not passed down the line. Obviously, obtaining several cells from an embryo will not compromise the survival and normal development of most embryos. Pre-implantation genetic diagnosis is also indicated for screening aneuploidy in women older than 35 years of age to address infertility or miscarriage in older women due to genetic abnormalities in the embryo; and for selecting genetically balanced embryos for transfer in couples with balanced translocations. It can fundamentally improve the pregnancy success rate of the first and second generation of IVF, reduce the rate of spontaneous abortion, improve the quality of pregnancy, and effectively avoid the necessity of terminating pregnancy during pregnancy due to the blind transfer of embryos carrying abnormal genes.